Friday, April 10, 2015 10:47:46 PM
Moving higher @ HZNP
We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We look forward to continuing our ongoing clinical development program as we evaluate ACTIMMUNE in this patient population."
Investor 100
We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We look forward to continuing our ongoing clinical development program as we evaluate ACTIMMUNE in this patient population."
Investor 100
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
